Towards a muscarinic hypothesis of schizophrenia

被引:211
作者
Raedler, T. J.
Bymaster, F. P.
Tandon, R.
Copolov, D.
Dean, B.
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Psychiat, D-20246 Hamburg, Germany
[2] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA
[3] State Florida, Dept Mental Hlth, Tallahassee, FL USA
[4] Mental Hlth Res Inst, Parkville, Vic, Australia
[5] Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia
[6] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia
[7] Monash Univ, Dept Med Psychol, Clayton, Vic 3168, Australia
关键词
schizophrenia; acetylcholine; receptors; muscarinic; muscarinic agonists; muscarinic antagonists; etiology;
D O I
10.1038/sj.mp.4001924
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although the neurotransmitter dopamine plays a prominent role in the pathogenesis and treatment of schizophrenia, the dopamine hypothesis of schizophrenia fails to explain all aspects of this disorder. It is increasingly evident that the pathology of schizophrenia also involves other neurotransmitter systems. Data from many streams of research including preclinical and clinical pharmacology, treatment studies, post-mortem studies and neuroimaging suggest an important role for the muscarinic cholinergic system in the pathophysiology of schizophrenia. This review will focus on evidence that supports the hypothesis that the muscarinic system is involved in the pathogenesis of schizophrenia and that muscarinic receptors may represent promising novel targets for the treatment of this disorder.
引用
收藏
页码:232 / 246
页数:15
相关论文
共 201 条
  • [1] Effects of rivastigmine on sustained attention in schizophrenia - An fMRI study
    Aasen, I
    Kumari, V
    Sharma, T
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (04) : 311 - 317
  • [2] Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
  • [3] Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
    Abi-Dargham, A
    Rodenhiser, J
    Printz, D
    Zea-Ponce, Y
    Gil, R
    Kegeles, LS
    Weiss, R
    Cooper, TB
    Mann, JJ
    Van Heertum, RL
    Gorman, JM
    Laruelle, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (14) : 8104 - 8109
  • [4] Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice
    Anagnostaras, SG
    Murphy, GG
    Hamilton, SE
    Mitchell, SL
    Rahnama, NP
    Nathanson, NM
    Silva, AJ
    [J]. NATURE NEUROSCIENCE, 2003, 6 (01) : 51 - 58
  • [5] The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys
    Andersen, MB
    Fink-Jensen, A
    Peacock, L
    Gerlach, J
    Bymaster, F
    Lundbæk, JA
    Werge, T
    [J]. NEUROPSYCHOPHARMACOLOGY, 2003, 28 (06) : 1168 - 1175
  • [6] [Anonymous], TRENDS NEUROSCI
  • [7] Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex
    Atzori, M
    Kanold, PO
    Pineda, JC
    Flores-Hernandez, J
    Paz, RD
    [J]. NEUROSCIENCE, 2005, 134 (04) : 1153 - 1165
  • [8] Baghdoyan HA, 1998, J PHARMACOL EXP THER, V286, P1446
  • [9] THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION
    BARTUS, RT
    DEAN, RL
    BEER, B
    LIPPA, AS
    [J]. SCIENCE, 1982, 217 (4558) : 408 - 417
  • [10] GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder
    Benes, FM
    Berretta, S
    [J]. NEUROPSYCHOPHARMACOLOGY, 2001, 25 (01) : 1 - 27